AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11152929
Drug: Tablet containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet containing 1-mg folic acid, 1-mg B12, and 25-mg B6
Trial: 11152929
Drug: Tablet containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet containing 2.5-mg folic acid, 1-mg B12, and 25-mg B6
Trial: 8378772
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of chicken type II collagen for 3 months
Trial: 27058753
Drug: CA19-9<466 U/ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CA19-9<466 U/ml
Trial: 27058753
Drug: CA19-9>571 U/ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CA19-9>571 U/ml
Trial: 22770683
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (medical treatment)
Trial: 15848983
Drug: Moisturizer containing
RxNorm normalized name: MOISTURIZER
DrugBank: Homosalate (DB11064)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Moisturizer containing urea applied twice daily for 20 days
Trial: 15848983
Drug: Patch tests
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patch tests with 0%, 0.5% and 2% NiSO4 in petrolatum
Trial: 12877666
Drug: Darbepoetin alfa
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Darbepoetin alfa 2.25 microg/kg, s.c., once weekly for 12 weeks
Trial: 11895470
Drug: Alcohol (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (3 units of ethanol daily for 1 week)
Trial: 7907261
Drug: FSH (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FSH (150 IU twice a week for 2 weeks, then 150 IU FSH and 250 IU hCG twice a week for 4 weeks)
Trial: 7907261
Drug: hCG (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hCG (250 IU twice a week for 6 weeks)
Trial: 31093742
Drug: ProTaper retreatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ProTaper retreatment instruments in combination with gutta‐percha solvent
Trial: 25939678
Drug: 4% topical
RxNorm normalized name: BPO 4% Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4% topical glycopyrrolate wipes
Trial: 25939678
Drug: 2% topical
RxNorm normalized name: A/T/S 2% Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% topical glycopyrrolate wipes
Trial: 21705552
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no HPP treatment)
Trial: 19379093
Drug: Aripiprazole (an
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aripiprazole (an antipsychotic)
Trial: 16817288
Drug: Heparin-coated perfusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-coated perfusion system (Group B)
Trial: 12771320
Drug: Dietary plant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary plant sterol ester (PSE) at a dosage of 2.8 g/d (1.68 g/d phytosterols) for 4 weeks
Trial: 10857945
Drug: Repaglinide (0.5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repaglinide (0.5, 1.0, 2.0 mg in study 1 and 4.0 mg in study 2)
Trial: 9118656
Drug: Group B
RxNorm normalized name: Blood group B IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B (1.5 g of amino acids/kg/day with 45% branch-chain amino acids)
Trial: 9118656
Drug: Group C
RxNorm normalized name: STREPTOCOCCUS ANTIGEN (GROUP C)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group C (1.1 g/kg/day of amino acids with 45% branch-chain amino acids)
Trial: 9118656
Drug: Group A
RxNorm normalized name: Blood group A IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A (1.5 g of amino acids/kg/day with 23% branch-chain amino acids)
Trial: 24809759
Drug: Controller medications
RxNorm normalized name: zinc pyrithione Medicated Shampoo [Dial Dandruff Control]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controller medications
Trial: 18598735
Drug: Sertraline (100-200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (100-200 mg/day)
Trial: 18598735
Drug: Fluoxetine (40-80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (40-80 mg/day)
Trial: 10320602
Drug: Ropivacaine 0.25%
RxNorm normalized name: ROPivacaine 0.25%-NaCl 0.9% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.25% (1.0 ml x kg(‐1))
Trial: 10320602
Drug: Bupivacaine 0.25%
RxNorm normalized name: BUPIVACAINE 0.25%/NS INJ 400ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 0.25% (1.0 ml x kg(‐1))
Trial: 7853584
Drug: 3 cycles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 cycles of 100 mg/m2 neoadjuvant cisplatin before radical cystectomy (arm B)
Trial: 1826253
Drug: prazosin (alpha
FDA approved: no
EMA approved: no
PMDA approved: no
Description: prazosin (alpha 1-adrenergic blocker)
Trial: 1826253
Drug: atenolol (cardioselective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: atenolol (cardioselective beta-adrenergic blocker)
Trial: 1826253
Drug: carteolol (nonselective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: carteolol (nonselective beta-adrenergic blocker)
Trial: 7036354
Drug: Clindamycin (IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin (IV therapy)
Trial: 7036354
Drug: Nafcillin/Methicillin (IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nafcillin/Methicillin (IV therapy)
Trial: 7036354
Drug: Clindamycin (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin (oral therapy)
Trial: 30794658
Drug: Celecoxib (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib (200 mg twice a day for 7 days)
Trial: 30794658
Drug: Placebo (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (200 mg twice a day for 7 days)
Trial: 26739737
Drug: 20 mL
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mL of physiological saline by an intrauterine catheter
Trial: 26739737
Drug: 10 mL
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mL of saline intravaginally
Trial: 24503560
Drug: Group B
RxNorm normalized name: Blood group B IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B (80 kV, 600 mAs, 50% reduction in contrast medium dose)
Trial: 22147447
Drug: Irinotecan (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan (50 mg/m² weekly), 5-fluorouracil (250 mg/m² for 5 days/week), pelvic radiation (45 Gy/1.8 Gy/fraction for 5 days/week)
Trial: 19021619
Drug: Intravesical alkalinized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravesical alkalinized lidocaine (PSD597) 200 mg lidocaine, alkalinized with 8.4% sodium bicarbonate solution, for 5 consecutive days
Trial: 12830369
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg ibandronate
Trial: 9844703
Drug: Epidural anesthesia
RxNorm normalized name: Epidural Anesthesia Tray
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epidural anesthesia with 150 micrograms clonidine in 15 ml bupivacaine 0.25% solution with 37.5 micrograms epinephrine (group C + E)
Trial: 9844703
Drug: Epidural anesthesia
RxNorm normalized name: Epidural Anesthesia Tray
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epidural anesthesia with 150 micrograms clonidine in 15 ml bupivacaine 0.25% solution without epinephrine (group C)
Trial: 8088613
Drug: High-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose chemotherapy with autologous bone marrow support (ABMS)
Trial: 8088613
Drug: High-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose chemotherapy regimens with ABMS (cyclophosphamide, cisplatin, thiotepa or cyclophosphamide, carboplatin, mitoxantrone)
Trial: 2684006
Drug: Furazolidone (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furazolidone (400 mg)
Trial: 4317858
Drug: 780 SE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 780 SE (300 mg)
Trial: 22234929
Drug: Guanfacine (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guanfacine (up to 3 mg)
Trial: 21947207
Drug: Plant stanols
RxNorm normalized name: plant stanol ester
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plant stanols (8.8 g/day for 10 weeks, followed by 4.5 g at breakfast)
Trial: 21947207
Drug: Plant stanols
RxNorm normalized name: plant stanol ester
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plant stanols (4.5 g at breakfast)
Trial: 21947207
Drug: Plant stanols
RxNorm normalized name: plant stanol ester
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plant stanols (8.8 g/day for 10 weeks)
Trial: 18840641
Drug: Oral ibandronate
RxNorm normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ibandronate 150 mg/month (n = 47)
Trial: 221871
Drug: High-dose conjugated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose conjugated estrogens with cyclic progesterone
Trial: 25920599
Drug: PDRN injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PDRN injection
Trial: 31484712
Drug: Inosine (mild
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inosine (mild or moderate dosing)
Trial: 31484712
Drug: Inosine (higher
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inosine (higher dosing)
Trial: 27138024
Drug: Aclidinium bromide
RxNorm normalized name: Aclidinium Bromide
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Aclidinium bromide 400 μg
Trial: 26549785
Drug: Glycopyrronium bromide
RxNorm normalized name: Glycopyrronium bromide
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Glycopyrronium bromide 50 μg
Trial: 23362890
Drug: Clonidine 50
RxNorm normalized name: cloNIDine 500 mcg/mL injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine 50 µg (Group C)
Trial: 23362890
Drug: Dexmedetomidine 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 5 µg (Group D)
Trial: 23362890
Drug: Hyperbaric bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric bupivacaine 0.5% 3 ml + saline 0.5 ml (Group B)
Trial: 19528362
Drug: Augmented volume
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Augmented volume removal therapy
Trial: 16732778
Drug: Recorded music
RxNorm normalized name: Recorlev
DrugBank: Levoketoconazole (DB05667)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recorded music therapy
Trial: 24092240
Drug: No music
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No music therapy
Trial: 10066844
Drug: Licostinel (0.03
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Licostinel (0.03 to 3.0 mg/kg)
Trial: 7726818
Drug: Methylphenidate (0.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate (0.7 mg/kg)
Trial: 7726818
Drug: Drug placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug placebo
Trial: 6102838
Drug: Beta-adrenergic receptor
RxNorm normalized name: Beta-adrenergic receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-adrenergic receptor blocking therapy
Trial: 20147617
Drug: Intravenous glycoprotein
RxNorm normalized name: Zaire ebolavirus envelope glycoprotein Injection [Ervebo]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous glycoprotein 2b/3a (GP2b/3a) antagonists
Trial: 12490017
Drug: Single intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intravenous dose of antibiotic (200 mg of ofloxacin) during anesthetic induction
Trial: 12490017
Drug: Treatment doses
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment doses of antibiotic (400 mg of ofloxacin per day) until the nephrostomy catheter was removed
Trial: 12490017
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (single-dose vs short-course)
Trial: 6256422
Drug: Methylprednisolone (MP)
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone (MP) treatment in vivo
Trial: 6256422
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of MP and histamine treatments
Trial: 29132988
Drug: PnuBioVax (50,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PnuBioVax (50, 200, 500 µg)
Trial: 29132988
Drug: PnuBioVax (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PnuBioVax (200 µg and 500 µg)
Trial: 24723075
Drug: Low-dose statin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose statin (LDS)
Trial: 24723075
Drug: FA +
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: FA + Low-dose statin (LDS)
Trial: 24723075
Drug: Moderate-dose statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate-dose statin (MDS)
Trial: 24723075
Drug: FA +
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: FA + Moderate-dose statin (MDS)
Trial: 24723075
Drug: High-dose statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose statin (HDS)
Trial: 21562420
Drug: 5 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 μg intrathecal hydromorphone
Trial: 21562420
Drug: 10 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 μg intrathecal hydromorphone
Trial: 21562420
Drug: 2.5 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 μg intrathecal hydromorphone
Trial: 21562420
Drug: 0.0 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.0 μg intrathecal hydromorphone (control group)
Trial: 17417700
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid (4 or 5 mg)
Trial: 16393308
Drug: 7-day RLT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-day RLT (rabeprazole 20 mg b.d., levofloxacin 500 mg b.d., tinidazole 500 mg b.d. for 7 days)
Trial: 16393308
Drug: 4-day RLT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-day RLT (rabeprazole 20 mg b.d., levofloxacin 500 mg b.d., tinidazole 500 mg b.d. for 4 days)
Trial: 11138570
Drug: 0.2 g
RxNorm normalized name: methionine 0.2 gram ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 g x kg(‐1) sodium citrate
Trial: 11138570
Drug: 0.4 g
RxNorm normalized name: psyllium 0.4 GM Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 g x kg(‐1) sodium citrate
Trial: 11138570
Drug: 0.6 g
RxNorm normalized name: Ceo-Two, 0.9 g-0.6 g rectal suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6 g x kg(‐1) sodium citrate
Trial: 11138570
Drug: Placebo (calcium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (calcium carbonate, 0.1 g x kg(‐1))
Trial: 8780802
Drug: Intravenous rt-PA
RxNorm normalized name: rt-PA
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous rt-PA (recombinant tissue plasminogen activator)
Trial: 8574724
Drug: Clonidine (0.150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (0.150 mg)
Trial: 29095681
Drug: Attention control
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Attention control (Taking-it-Easy relaxation therapy)
Trial: 11525706
Drug: Crotalinae polyvalent
RxNorm normalized name: polyvalent Crotalidae antivenin
DrugBank: Viper antivenom (DB14114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crotalinae polyvalent immune Fab (Fab AV) - Scheduled group (initial dose plus repeated treatments)
Trial: 9589688
Drug: DHEA (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEA (50 mg daily for 2 weeks)
Trial: 29182708
Drug: B-vitamin therapy
RxNorm normalized name: VITAMIN B
DrugBank: Inositol (DB13178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: B-vitamin therapy (daily multivitamin with 5.0 mg folate, 1.0 mg vitamin B12, 50 mg vitamin B6)
Trial: 29182708
Drug: Placebo (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (daily multi-vitamin with no folate, 2.0 µg vitamin B12, 1.4 mg vitamin B6)
Trial: 23615159
Drug: Edoxaban 60
RxNorm normalized name: edoxaban 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edoxaban 60 mg coadministered with low-dose ASA (100 mg)
Trial: 23615159
Drug: Edoxaban 60
RxNorm normalized name: edoxaban 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edoxaban 60 mg coadministered with high-dose ASA (325 mg)
Trial: 23615159
Drug: Edoxaban 60
RxNorm normalized name: edoxaban 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edoxaban 60 mg coadministered with naproxen (500 mg)
Trial: 21544078
Drug: NPO‐11 (L-menthol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NPO‐11 (L-menthol preparation)
Trial: 8526176
Drug: Both drugs
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both drugs (BUD and BDP)
Trial: 6107099
Drug: i.v. diazepam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. diazepam (titrated doses)
Trial: 6107099
Drug: Both oral
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both oral temazepam and i.v. diazepam
Trial: 6134547
Drug: Oral temazepam
RxNorm normalized name: Temazepam
DrugBank: Temazepam acetate (DB14671)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral temazepam
Trial: 31039261
Drug: Mindfulness-based stress
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-based stress reduction program, sessions of 90 to 95 minutes, twice per week for 12 weeks
Trial: 27140797
Drug: Fasiglifam 50
RxNorm normalized name: Fasiglifam
DrugBank: Fasiglifam (DB12491)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fasiglifam 50 mg
Trial: 27140797
Drug: Fasiglifam 400
RxNorm normalized name: Fasiglifam
DrugBank: Fasiglifam (DB12491)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fasiglifam 400 mg
Trial: 16899485
Drug: Subcutaneous treprostinil
RxNorm normalized name: Treprostinil
DrugBank: Treprostinil (DB00374)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Subcutaneous treprostinil
Trial: 15460380
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral treatment protocol
Trial: 10733114
Drug: Erythromycin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin (200 mg IV every 6 hours)
Trial: 31979305
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg of EGCG and 60 mL of coconut oil
Trial: 31090592
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (allo‐PBS and CBS)
Trial: 15328178
Drug: Arzoxifene 20
RxNorm normalized name: Arzoxifene
DrugBank: Arzoxifene (DB06249)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arzoxifene 20 mg daily
Trial: 19815891
Drug: 21-day doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 21-day doxycycline (200 mg/day) followed by single-dose diethylcarbamazine
Trial: 19815891
Drug: 10-day doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10-day doxycycline (200 mg/day) followed by single-dose diethylcarbamazine
Trial: 19815891
Drug: 21-day doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 21-day doxycycline (200 mg/day)
Trial: 19815891
Drug: 10-day doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10-day doxycycline (200 mg/day)
Trial: 15121364
Drug: Total anterior
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total anterior capsule cover (360 degrees) of the optic
Trial: 15121364
Drug: No anterior
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No anterior capsule cover (360 degrees) of the optic
Trial: 15121364
Drug: Partial anterior
RxNorm normalized name: rosin partially dimerized glycerol ester
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Partial anterior capsule cover (<360 degrees) of the optic
Trial: 11287037
Drug: Serum hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Serum hormone concentrations in 4R‐‐ individuals
Trial: 3427209
Drug: Cefuroxime axetil
RxNorm normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefuroxime axetil 500 mg (fed)
Trial: 3427209
Drug: Cefuroxime axetil
RxNorm normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefuroxime axetil 500 mg (fasted)
Trial: 3427209
Drug: Cefuroxime axetil
RxNorm normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefuroxime axetil (various doses)
Trial: 2203940
Drug: Chemotherapy (including
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (including PCVm and ACVD regimens)
Trial: 2203940
Drug: Maintenance therapy
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance therapy (NB 82)
Trial: 2203940
Drug: Shorter intervals
RxNorm normalized name: SALICYLIC ACID 2 mg in 100 mL TOPICAL SHAMPOO [FYENACEL CALMING SHOOTER CELLANDIR HAIR LOSS-Shampoo]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shorter intervals for realization of chemotherapy (NB 85)
Trial: 165029
Drug: tibric acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tibric acid 1,000 mg